MARKET

HOWL

HOWL

Werewolf Therapeutics, Inc.
NASDAQ
0.9466
-0.0391
-3.97%
After Hours: 0.9500 +0.0034 +0.36% 17:28 11/20 EST
OPEN
0.9546
PREV CLOSE
0.9857
HIGH
0.9899
LOW
0.9300
VOLUME
373.05K
TURNOVER
--
52 WEEK HIGH
1.200
52 WEEK LOW
0.2700
MARKET CAP
45.68M
P/E (TTM)
-1.6229
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at HOWL last week (1109-1113)?
Weekly Report · 4d ago
Werewolf Therapeutics, Inc. Announces Clinical Data for WTX-124 and WTX-330
NASDAQ · 11/09 21:22
Werewolf Therapeutics Reports Positive WTX-124 and WTX-330 Clinical Data
TipRanks · 11/09 14:48
Werewolf Therapeutics announces new clinical data from WTX-124 trial
TipRanks · 11/09 14:18
Weekly Report: what happened at HOWL last week (1102-1106)?
Weekly Report · 11/09 09:43
Weekly Report: what happened at HOWL last week (1026-1030)?
Weekly Report · 11/02 09:42
Werewolf Therapeutics To Present Two Posters On WTX-124, WTX-330 Data At Upcoming SITC 2026 Annual Meeting
Benzinga · 10/30 12:33
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 10/27 21:05
More
About HOWL
Werewolf Therapeutics, Inc. is a biopharmaceutical company engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s advanced clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. It is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. It is advancing WTX-712, WTX-518, and WTX-921 through preclinical development.

Webull offers Werewolf Therapeutics Inc stock information, including NASDAQ: HOWL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HOWL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HOWL stock methods without spending real money on the virtual paper trading platform.